PTPN2 mutations cause epithelium-intrinsic barrier loss that synergizes with mucosal immune hyperactivation.
Where this comes from
- Record sourced from PubMed, PMID 34623321.
- Also identified by DOI 10.1172/JCI151414 and PMC identifier 8409575.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It is clear that excessive mucosal immune activation and intestinal barrier dysfunction both contribute to inflammatory bowel disease (IBD) pathogenesis. T cell protein tyrosine phosphatase (TCPTP), which extinguishes signaling in immune cells, is linked to IBD and other immune-mediated diseases. In this issue of the JCI, Marchelletta and Krishnan et al. demonstrate that, in intestinal epithelial cells, TCPTP regulates tight junction permeability in vivo. Intestinal epithelial TCPTP loss potentiated cytokine-induced barrier loss, and this synergized with effects of TCPTP loss in immune cells. This work implicates a single mutation as the cause of distinct functional aberrations in diverse cell types and demonstrates how one genetic defect can drive multihit disease pathogenesis.
Medical subject headings
- Inflammatory Bowel Diseases
- Protein Tyrosine Phosphatase, Non-Receptor Type 2